Sun Pharmaceutical Industries reported a 20% decline in net profit for Q1 FY26, standing at ₹2,279 crore. The fall is ...

Sun Pharmaceutical Industries reported a 20% decline in net profit for Q1 FY26, but adjusted profits excluding exceptions ...

Sun Pharmaceutical Industries on Thursday said its consolidated net profit declined 20 per cent year-on-year to Rs 2,279 ...

Sun Pharmaceutical Industries reported a 20% fall in Q1 consolidated net profit, reaching Rs 2,278 crore. Despite this dip, ...

Sun Pharma's Q1 net profit fell 20% YoY to Rs 2,279 crore, while adjusted net profit rose 6%. India market showed strong momentum. Leqselvi US launch announced.

Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently available to health care providers and adults suffering from severe alopecia ...

India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

The approval of Leqselvi for adults with severe alopecia areata (at least 50% scalp hair loss) was based on positive results from two phase 3 clinical trials: THRIVE-AA1 (ClinicalTrials.gov ...

LEQSELVI should not be used by women who are breastfeeding until one day after the last dose. LEQSELVI should not be used by patients with severe renal impairment or severe hepatic impairment.

LEQSELVI demonstrated rapid results in clinical trials with one third of patients regaining almost all of their hair by Week 24. Some patients (3%) achieved 80% or more scalp coverage as fast as 8 ...

As part of the agreement, Incyte has granted Sun Pharma a limited, non-exclusive license to US Patent Nos. 9,662,335 and other related patents.

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...